Orforglipron may not surpass the efficacy benchmarks set by injectables like tirzepatide or semaglutide, but its superior convenience over existing oral options might make effective GLP-1 therapy accessible to more patients
Clinical trials have demonstrated that semaglutide produces substantial weight loss when combined with lifestyle modifications including reduced caloric intake and increased physical activity
By boosting filaggrin, GFF helps strengthen both our barrier and our skin's ability to retain moisture
Safety monitoring should include periodic IGF-1 levels and fasting glucose checks, as growth hormone stimulation can affect glucose metabolism
Core muscle strength may not immediately adapt to changing body composition, potentially causing increased mechanical stress on the lumbar spine, though this mechanism remains hypothetical for pharmacologic weight loss
Ozempic (semaglutide) is a GLP-1 receptor agonist licensed in the UK for type 2 diabetes mellitus treatment